ALM-006 is under clinical development by Almatica Pharma and currently in Phase III for Substance (Drug) Abuse. According to GlobalData, Phase III drugs for Substance (Drug) Abuse have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how ALM-006’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALM-006 overview
ALM-006 is under development for the treatment of substance use disorder.
Almatica Pharma overview
Almatica Pharma Inc (Almatica), a subsidiary of Alvogen Inc, is a pharmaceutical company. The company focuses on the development, manufacturing and commercialization of generic, brand, OTC and biosimilar products. It provides its products in the form of capsules and tablets. Almatica offers products in the therapeutic areas of psychiatry, pain management, anti-infectives and cardiovascular-related disorders. The company has manufacturing, research and manufacturing facilities in the US, South Korea and Romania. It seeks to partner with other companies to expand its US product portfolio through in-licensing and acquisition of products. Almatica is headquartered in Morristown, New Jersey, the US.
For a complete picture of ALM-006’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
